Elvitegravir once-daily is non inferior to raltegravir twice-daily in treatment experienced patients: 48 week results from a phase 3 multicenter, randomized, double blind study

WELBB05

---

Time: 17:10
Speaker: Jean-Michel Molina

You can download the mp3 file here

For more information on this presentation, including access to speaker presentations, please see the conference Programme-at-a-Glance page.